Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Regulus Therapeutics Inc ( ($RGLS) ) has released its Q4 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Targeted chemotherapy in the abdomen using a technique called PIPAC combined with systemic standard-of-care chemotherapy is shown to be safe, with promising activity for patients with colorectal and a ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer. Shares were trading around $10.35. The stock is ...